Trader Sarepta Therapeutics, Inc. - SRPT CFD
Ajouter aux favoris- Résumé
- Données historiques
- Événements
- Compte de résultat
- Bilan
- Flux de trésorerie
- Capital
Conditions de trading
| Écart | 0.26 | ||||||||
|
Frais de position longue en overnight
Long position overnight fee
Aller vers la plateforme | -0.025457% | ||||||||
|
Frais de position courte en overnight
Short position overnight fee
Aller vers la plateforme | 0.003235% | ||||||||
| Durée des frais en overnight | 21:00 (UTC) | ||||||||
| Quantité minimale négociée | 1 | ||||||||
| Devise | USD | ||||||||
| Marge | 20% | ||||||||
| Bourse | United States of America | ||||||||
| Commission sur la négociation | 0% |
*Information provided by Capital.com
Sarepta Therapeutics Inc ESG Risk Ratings
High Medium Low Negligible
‘C’ score indicates satisfactory relative ESG performance and moderate degree of transparency in reporting material ESG data publicly.
Chiffres clés
| Fermeture précédente* | 123.72 |
| Ouvert* | 125.06 |
| Variation sur 1 an* | 72.57% |
| Fourchette du jour* | 124.45 - 126 |
| Fourchette sur 52 semaines | 61.28-159.89 |
| Volume moyen (10 jours) | 1.65M |
| Volume moyen (3 mois) | 36.46M |
| Capitalisation boursière | 11.51B |
| Ratio C/B | -100.00K |
| Actions en circulation | 93.15M |
| Revenu | 975.68M |
| EPS | -12.69 |
| Dividende (rendement en %) | N/A |
| Bêta | 1.00 |
| Prochaine date de publication des résultats | Jul 31, 2023 |
Toutes les données sont fournies par Refinitiv, à l'exception des données marquées d'un astérisque, qui sont des *données fournies par Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Clôture | Change | Change (%) | Ouverture | High | Low |
|---|---|---|---|---|---|---|
| Jun 1, 2023 | 123.72 | 0.23 | 0.19% | 123.49 | 125.35 | 121.44 |
| May 31, 2023 | 123.23 | -1.16 | -0.93% | 124.39 | 125.49 | 122.59 |
| May 30, 2023 | 124.72 | -2.16 | -1.70% | 126.88 | 127.55 | 123.89 |
| May 26, 2023 | 126.70 | -1.43 | -1.12% | 128.13 | 128.70 | 125.73 |
| May 25, 2023 | 128.29 | -0.56 | -0.43% | 128.85 | 130.79 | 125.20 |
| May 24, 2023 | 130.77 | -3.49 | -2.60% | 134.26 | 138.75 | 128.06 |
| May 23, 2023 | 146.34 | -0.46 | -0.31% | 146.80 | 149.96 | 146.15 |
| May 22, 2023 | 148.60 | 0.51 | 0.34% | 148.09 | 151.64 | 148.05 |
| May 19, 2023 | 148.45 | 1.54 | 1.05% | 146.91 | 149.24 | 145.47 |
| May 18, 2023 | 146.04 | -1.49 | -1.01% | 147.53 | 148.58 | 144.09 |
| May 17, 2023 | 148.30 | -0.15 | -0.10% | 148.45 | 149.82 | 144.53 |
| May 16, 2023 | 148.31 | -4.88 | -3.19% | 153.19 | 153.43 | 147.50 |
| May 15, 2023 | 155.77 | 6.59 | 4.42% | 149.18 | 159.63 | 146.35 |
| May 11, 2023 | 119.53 | -0.42 | -0.35% | 119.95 | 120.23 | 113.09 |
| May 10, 2023 | 120.52 | -11.25 | -8.54% | 131.77 | 134.60 | 120.52 |
| May 9, 2023 | 124.84 | -0.03 | -0.02% | 124.87 | 128.53 | 124.09 |
| May 8, 2023 | 126.68 | -4.16 | -3.18% | 130.84 | 130.84 | 125.74 |
| May 5, 2023 | 130.88 | 1.45 | 1.12% | 129.43 | 132.26 | 128.46 |
| May 4, 2023 | 129.54 | 4.30 | 3.43% | 125.24 | 130.86 | 124.64 |
| May 3, 2023 | 125.14 | 5.68 | 4.75% | 119.46 | 126.45 | 119.46 |
Sarepta Therapeutics, Inc. Events
| Heure (UTC) (UTC) | Pays | Événement |
|---|---|---|
| Thursday, June 8, 2023 | ||
| Heure (UTC) (UTC) 14:00 | Pays US
| Événement Sarepta Therapeutics Inc Annual Shareholders Meeting Sarepta Therapeutics Inc Annual Shareholders MeetingForecast -Previous - |
| Monday, July 31, 2023 | ||
| Heure (UTC) (UTC) 10:59 | Pays US
| Événement Q2 2023 Sarepta Therapeutics Inc Earnings Release Q2 2023 Sarepta Therapeutics Inc Earnings ReleaseForecast -Previous - |
| Tuesday, October 31, 2023 | ||
| Heure (UTC) (UTC) 10:59 | Pays US
| Événement Q3 2023 Sarepta Therapeutics Inc Earnings Release Q3 2023 Sarepta Therapeutics Inc Earnings ReleaseForecast -Previous - |
- Annuel
- Trimestriel
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
| Revenu total | 933.013 | 701.887 | 540.099 | 380.833 | 301.034 |
| Revenu | 933.013 | 701.887 | 540.099 | 380.833 | 301.034 |
| Coût des recettes, total | 139.989 | 97.049 | 63.382 | 56.586 | 34.193 |
| Résultat brut | 793.024 | 604.838 | 476.717 | 324.247 | 266.841 |
| Total des frais d'exploitation | 1597.23 | 1064.08 | 996.193 | 1086.4 | 644.662 |
| Total des frais de vente/Généraux/Admin | 451.421 | 282.66 | 317.875 | 284.812 | 207.761 |
| Recherche et développement | 877.09 | 771.182 | 722.343 | 560.909 | 401.843 |
| Produits d'exploitation | -664.217 | -362.198 | -456.094 | -705.563 | -343.628 |
| Produits (charges) d'intérêts, nets Hors exploitation | -30.06 | -55.971 | -101.977 | -18.982 | |
| Résultat net avant impôts | -689.963 | -418.948 | -553.065 | -713.88 | -362.61 |
| Résultat net après impôts | -703.488 | -418.78 | -554.128 | -715.075 | -361.918 |
| Résultat net avant éléments extra | -703.488 | -418.78 | -554.128 | -715.075 | -361.918 |
| Résultat net | -703.488 | -418.78 | -554.128 | -715.075 | -361.918 |
| Revenu disponible pour les actionnaires ordinaires, hors éléments exceptionnels | -703.488 | -418.78 | -554.128 | -715.075 | -361.918 |
| Bénéfice disponible pour les actionnaires ordinaires, y compris les éléments exceptionnels | -703.488 | -418.78 | -554.128 | -715.075 | -361.918 |
| Résultat net dilué | -703.488 | -418.78 | -554.128 | -715.075 | -361.918 |
| Moyenne pondérée des actions diluées | 87.559 | 81.262 | 77.956 | 73.615 | 66.25 |
| BPA dilué hors éléments extraordinaires | -8.03445 | -5.15345 | -7.10821 | -9.71371 | -5.46291 |
| BPA dilué normalisé | -7.08411 | -5.85345 | -8.0093 | -7.27209 | -5.46291 |
| Depreciation / Amortization | 0.714 | 0.706 | 0.662 | 0.849 | 0.865 |
| Charges (revenus) inhabituelles | 128.016 | -87.512 | -108.069 | 183.24 | 0 |
| Autres, nets | 4.314 | -0.779 | 5.006 | -8.317 |
| Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
|---|---|---|---|---|---|
| Revenu total | 253.5 | 258.427 | 230.269 | 233.487 | 210.83 |
| Revenu | 253.5 | 258.427 | 230.269 | 233.487 | 210.83 |
| Coût des recettes, total | 35.017 | 30.799 | 39.952 | 37.795 | 31.443 |
| Résultat brut | 218.483 | 227.628 | 190.317 | 195.692 | 179.387 |
| Total des frais d'exploitation | 778.917 | 367.835 | 487.065 | 444.619 | 297.711 |
| Total des frais de vente/Généraux/Admin | 110.714 | 120.478 | 104.787 | 154.316 | 71.84 |
| Recherche et développement | 245.679 | 213.804 | 216.707 | 252.329 | 194.25 |
| Depreciation / Amortization | 0.178 | 0.179 | 0.178 | 0.179 | 0.178 |
| Charges (revenus) inhabituelles | 387.329 | 2.575 | 125.441 | 0 | 0 |
| Produits d'exploitation | -525.417 | -109.408 | -256.796 | -211.132 | -86.881 |
| Produits (charges) d'intérêts, nets Hors exploitation | 2.953 | 2.438 | -3.256 | -13.619 | -15.623 |
| Autres, nets | 9.754 | 5.664 | 3.634 | -3.342 | -1.642 |
| Résultat net avant impôts | -512.71 | -101.306 | -256.418 | -228.093 | -104.146 |
| Résultat net après impôts | -516.755 | -109.244 | -257.738 | -231.481 | -105.025 |
| Résultat net avant éléments extra | -516.755 | -109.244 | -257.738 | -231.481 | -105.025 |
| Résultat net | -516.755 | -109.244 | -257.738 | -231.481 | -105.025 |
| Revenu disponible pour les actionnaires ordinaires, hors éléments exceptionnels | -516.755 | -109.244 | -257.738 | -231.481 | -105.025 |
| Bénéfice disponible pour les actionnaires ordinaires, y compris les éléments exceptionnels | -516.755 | -109.244 | -257.738 | -231.481 | -105.025 |
| Résultat net dilué | -516.755 | -109.244 | -257.738 | -231.481 | -105.025 |
| Moyenne pondérée des actions diluées | 88.186 | 87.841 | 87.628 | 87.511 | 87.253 |
| BPA dilué hors éléments extraordinaires | -5.85983 | -1.24366 | -2.94127 | -2.64516 | -1.20368 |
| Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
| BPA dilué normalisé | -3.00491 | -1.2246 | -2.01079 | -2.64516 | -1.20368 |
- Annuel
- Trimestriel
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
| Total de l'actif à court terme | 2557.86 | 2604.1 | 2485.2 | 1468.91 | 1426.18 |
| Espèces et placements à court terme | 1989.37 | 2115.87 | 1938.57 | 1124.75 | 1173.91 |
| Trésorerie et équivalents | 966.777 | 2115.87 | 1502.65 | 835.08 | 370.829 |
| Investissements à court terme | 1022.6 | 0 | 435.923 | 289.668 | 803.083 |
| Total des créances, nettes | 259.697 | 171.637 | 138.583 | 93.938 | 64.436 |
| Accounts Receivable - Trade, Net | 214.628 | 152.99 | 101.34 | 90.879 | 49.044 |
| Total Inventory | 203.968 | 186.212 | 231.961 | 171.379 | 125.445 |
| Prepaid Expenses | 30.645 | 30.583 | 37.586 | 19.323 | 22.006 |
| Other Current Assets, Total | 74.177 | 99.798 | 138.495 | 59.525 | 40.384 |
| Total Assets | 3128.37 | 3147.97 | 2984.72 | 1822.82 | 1642.07 |
| Property/Plant/Equipment, Total - Net | 244.991 | 236.687 | 282.191 | 167.553 | 97.024 |
| Property/Plant/Equipment, Total - Gross | 393.867 | 349.319 | 358.218 | 218.548 | 125.173 |
| Accumulated Depreciation, Total | -148.876 | -112.632 | -76.027 | -50.995 | -28.149 |
| Intangibles, Net | 7.578 | 14.239 | 13.628 | 12.497 | 11.574 |
| Other Long Term Assets, Total | 286.615 | 258.057 | 164.904 | 141.922 | 75.555 |
| Total Current Liabilities | 619.604 | 452.733 | 416.026 | 264.767 | 173.69 |
| Accounts Payable | 95.875 | 76.741 | 111.09 | 68.094 | 33.829 |
| Accrued Expenses | 353.18 | 224.601 | 171.865 | 148.124 | 107.648 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
| Current Port. of LT Debt/Capital Leases | 0 | ||||
| Other Current Liabilities, Total | 170.549 | 151.391 | 133.071 | 48.549 | 32.213 |
| Total Liabilities | 2743.42 | 2219.97 | 2222.96 | 1004.64 | 609.799 |
| Total Long Term Debt | 1544.29 | 1096.88 | 992.493 | 681.9 | 420.554 |
| Long Term Debt | 1544.29 | 1096.88 | 992.493 | 681.9 | 420.554 |
| Other Liabilities, Total | 579.52 | 670.356 | 814.44 | 57.968 | 15.555 |
| Total Equity | 384.95 | 928.009 | 761.759 | 818.187 | 1032.28 |
| Preferred Stock - Non Redeemable, Net | 0 | 0 | 0 | 0 | |
| Common Stock | 0.009 | 0.009 | 0.008 | 0.008 | 0.007 |
| Additional Paid-In Capital | 4296.84 | 4134.77 | 3609.88 | 3112.13 | 2611.29 |
| Retained Earnings (Accumulated Deficit) | -3910.24 | -3206.75 | -2848.13 | -2294 | -1578.93 |
| Other Equity, Total | -1.664 | -0.02 | 0.003 | 0.05 | -0.099 |
| Total Liabilities & Shareholders’ Equity | 3128.37 | 3147.97 | 2984.72 | 1822.82 | 1642.07 |
| Total Common Shares Outstanding | 87.9501 | 87.127 | 79.3743 | 75.1849 | 71.0719 |
| Long Term Investments | 31.321 | 34.892 | 38.799 | 31.937 | 31.739 |
| Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
|---|---|---|---|---|---|
| Total de l'actif à court terme | 2488.38 | 2557.86 | 2625.93 | 2469.3 | 2530.95 |
| Espèces et placements à court terme | 1882.1 | 1989.37 | 2072.48 | 1928.02 | 2013.43 |
| Trésorerie et équivalents | 871.668 | 966.777 | 1038.62 | 868.565 | 1233.88 |
| Investissements à court terme | 1010.43 | 1022.6 | 1033.86 | 1059.45 | 779.548 |
| Total des créances, nettes | 288.076 | 259.697 | 223.45 | 230.275 | 197.201 |
| Accounts Receivable - Trade, Net | 223.836 | 214.628 | 201.509 | 203.854 | 178.194 |
| Total Inventory | 202.675 | 203.968 | 221.192 | 208.095 | 198.997 |
| Prepaid Expenses | 28.73 | 30.645 | 25.392 | 23.604 | 25.766 |
| Other Current Assets, Total | 86.799 | 74.177 | 83.411 | 79.307 | 95.558 |
| Total Assets | 3059.79 | 3128.37 | 3156.15 | 2996.85 | 3056.15 |
| Property/Plant/Equipment, Total - Net | 244.878 | 244.991 | 224.039 | 230.291 | 233.23 |
| Intangibles, Net | 7.199 | 7.578 | 13.057 | 13.062 | 13.328 |
| Long Term Investments | 31 | 31.321 | 33.244 | 33.234 | 33.394 |
| Other Long Term Assets, Total | 288.332 | 286.615 | 259.88 | 250.966 | 245.255 |
| Total Current Liabilities | 536.884 | 619.604 | 602.916 | 545.566 | 454.962 |
| Accounts Payable | 106.71 | 95.875 | 118.461 | 56.207 | 54.007 |
| Accrued Expenses | 260.77 | 353.18 | 301.056 | 315.338 | 224.935 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities, Total | 169.404 | 170.549 | 183.399 | 174.021 | 176.02 |
| Total Liabilities | 2347.04 | 2743.42 | 2725.31 | 2270.4 | 2199.27 |
| Total Long Term Debt | 1234.28 | 1544.29 | 1542.77 | 1100.87 | 1098.85 |
| Long Term Debt | 1234.28 | 1544.29 | 1542.77 | 1100.87 | 1098.85 |
| Other Liabilities, Total | 575.869 | 579.52 | 579.623 | 623.957 | 645.459 |
| Total Equity | 712.749 | 384.95 | 430.84 | 726.457 | 856.886 |
| Common Stock | 0.009 | 0.009 | 0.009 | 0.009 | 0.009 |
| Additional Paid-In Capital | 5140.15 | 4296.84 | 4235.03 | 4272.19 | 4168.96 |
| Retained Earnings (Accumulated Deficit) | -4426.99 | -3910.24 | -3800.99 | -3543.25 | -3311.77 |
| Other Equity, Total | -0.419 | -1.664 | -3.205 | -2.485 | -0.306 |
| Total Liabilities & Shareholders’ Equity | 3059.79 | 3128.37 | 3156.15 | 2996.85 | 3056.15 |
| Total Common Shares Outstanding | 93.1401 | 87.9501 | 87.7662 | 87.5353 | 87.4956 |
| Preferred Stock - Non Redeemable, Net | 0 | 0 | 0 | 0 | 0 |
| Property/Plant/Equipment, Total - Gross | |||||
| Accumulated Depreciation, Total |
- Annuel
- Trimestriel
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
| Revenu net/Ligne de départ | -703.488 | -418.78 | -554.128 | -715.075 | -361.918 |
| Liquidités provenant des activités d'exploitation | -325.346 | -443.172 | 107.466 | -456.463 | -388.66 |
| Liquidités provenant des activités d'exploitation | 41.864 | 38.017 | 26.911 | 30.547 | 12.245 |
| Éléments non monétaires | 375.748 | 35.757 | 80.627 | 294.946 | 68.905 |
| Intérêts payés en espèces | 44.418 | 55.949 | 34.418 | 8.55 | 11.308 |
| Variation du fonds de roulement | -39.47 | -98.166 | 554.056 | -66.881 | -107.892 |
| Flux de trésorerie liés aux activités d'investissement | -1046.88 | 495.413 | -121.721 | 286.725 | -370.488 |
| Dépenses d'investissement | -30.824 | -38.49 | -82.202 | -62.713 | -64.345 |
| Autres éléments de flux de trésorerie d'investissement, total | -1016.06 | 533.903 | -39.519 | 349.438 | -306.143 |
| Flux de trésorerie provenant des activités de financement | 232.507 | 561.569 | 682.323 | 642.554 | 530.15 |
| Émission (remboursement) d'actions, nette | -70.945 | 569.334 | 396.01 | 401.955 | 563.631 |
| Émission (remboursement) de la dette, nette | 304.168 | 0 | 291.15 | 245.625 | -33.481 |
| Variation nette de la trésorerie | -1139.72 | 613.81 | 668.068 | 472.816 | -228.998 |
| Cash Taxes Paid | 1.695 | 0.583 | 2.51 | 0.933 | 1.548 |
| Éléments de flux de trésorerie de financement | -0.716 | -7.765 | -4.837 | -5.026 | 0 |
| Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
|---|---|---|---|---|---|
| Net income/Starting Line | -516.755 | -703.488 | -594.244 | -336.506 | -105.025 |
| Cash From Operating Activities | -209.396 | -325.346 | -232.954 | -167.99 | -101.175 |
| Cash From Operating Activities | 11.305 | 41.864 | 31.311 | 20.608 | 10.719 |
| Non-Cash Items | 425.11 | 375.748 | 318.056 | 145.971 | 36.648 |
| Cash Interest Paid | 7.023 | 44.418 | 41.273 | 27.78 | 11.688 |
| Changes in Working Capital | -129.056 | -39.47 | 11.923 | 1.937 | -43.517 |
| Cash From Investing Activities | 12.492 | -1046.88 | -1056.68 | -1075.8 | -785.807 |
| Capital Expenditures | -9.485 | -30.824 | -22.86 | -14.629 | -5.551 |
| Other Investing Cash Flow Items, Total | 21.977 | -1016.06 | -1033.82 | -1061.17 | -780.256 |
| Cash From Financing Activities | 101.795 | 232.507 | 221.758 | 5.329 | 4.99 |
| Financing Cash Flow Items | -6.887 | -0.716 | -0.162 | 0 | 0 |
| Issuance (Retirement) of Stock, Net | 108.682 | -70.945 | -82.248 | 5.329 | 4.99 |
| Net Change in Cash | -95.109 | -1139.72 | -1067.88 | -1238.46 | -881.992 |
| Issuance (Retirement) of Debt, Net | 304.168 | 304.168 |
| Nom de l'investisseur | Catégorie de l'investisseur | Pourcentage de l'encours | Actions détenues | Changement d'actions | Date d'avoirs | Taux du chiffre d'affaires |
|---|---|---|---|---|---|---|
| The Vanguard Group, Inc. | Investment Advisor/Hedge Fund | 8.693 | 8097450 | 79700 | 2023-03-31 | LOW |
| Janus Henderson Investors | Investment Advisor/Hedge Fund | 5.2692 | 4908204 | -1119812 | 2023-03-31 | LOW |
| BlackRock Institutional Trust Company, N.A. | Investment Advisor | 4.2812 | 3987871 | -30286 | 2023-03-31 | LOW |
| Avoro Capital Advisors LLC | Investment Advisor/Hedge Fund | 3.9185 | 3650000 | 475000 | 2023-03-31 | LOW |
| Barry (Richard J) | Individual Investor | 3.3584 | 3128319 | 1430 | 2023-04-14 | LOW |
| EcoR1 Capital, LLC | Hedge Fund | 3.2201 | 2999453 | 0 | 2023-03-31 | LOW |
| Wellington Management Company, LLP | Investment Advisor/Hedge Fund | 3.1494 | 2933612 | 379548 | 2023-03-31 | LOW |
| JP Morgan Asset Management | Investment Advisor | 3.1009 | 2888483 | 2405135 | 2023-03-31 | LOW |
| Two Sigma Investments, LP | Hedge Fund | 2.4401 | 2272877 | 971837 | 2023-03-31 | HIGH |
| Fidelity Management & Research Company LLC | Investment Advisor | 2.4199 | 2254083 | 19413 | 2023-03-31 | LOW |
| State Street Global Advisors (US) | Investment Advisor/Hedge Fund | 1.9045 | 1773976 | -167768 | 2023-03-31 | LOW |
| Geode Capital Management, L.L.C. | Investment Advisor/Hedge Fund | 1.3548 | 1261971 | 43239 | 2023-03-31 | LOW |
| Mellon Investments Corporation | Investment Advisor/Hedge Fund | 1.3135 | 1223537 | 25601 | 2023-03-31 | LOW |
| Pictet Asset Management Ltd. | Investment Advisor/Hedge Fund | 1.3026 | 1213356 | 282713 | 2023-03-31 | LOW |
| Casdin Capital, LLC | Hedge Fund | 1.2453 | 1160000 | -155000 | 2023-03-31 | MED |
| T. Rowe Price Associates, Inc. | Investment Advisor | 1.2066 | 1123923 | 334496 | 2023-03-31 | LOW |
| American Century Investment Management, Inc. | Investment Advisor/Hedge Fund | 1.0233 | 953204 | 270542 | 2023-03-31 | LOW |
| Farallon Capital Management, L.L.C. | Hedge Fund | 0.9805 | 913300 | -15600 | 2023-03-31 | MED |
| DWS Investment GmbH | Investment Advisor/Hedge Fund | 0.9456 | 880796 | -33023 | 2023-03-31 | LOW |
| Sands Capital Management, LLC | Investment Advisor | 0.9391 | 874765 | -1276613 | 2023-03-31 | LOW |
Pourquoi choisir capital.com? Nos chiffres parlent d'eux-mêmes.
Capital.com Group535K+
Tradeurs
87K+
Clients actifs par mois
$113M+
Volume d'investissement par mois
$64M+
Retrait par mois
Trading calculator
Calculez votre P&L hypothétique si vous aviez ouvert une transaction CFD à une certaine date (sélectionnez une date) et l'aviez fermée à une autre date (sélectionnez une date).
Trade commission
0
- 1:1
Effet de levier
1:1
- 20
- 100
- 500
- 1000
- 10000
Investment
Trade size (Leverage x Investement):
Ouverture
Clôture
Short Long
Sarepta Company profile
À propos de Sarepta Therapeutics, Inc.
Sarepta Therapeutics, Inc. est une société biopharmaceutique en phase de commercialisation. La société se concentre sur l'aide aux patients par la découverte et le développement de thérapies ciblées par l'acide ribonucléique (ARN), la thérapie génique et d'autres modalités thérapeutiques génétiques pour le traitement de maladies rares. Elle développe des candidats thérapeutiques pour une série de maladies et de troubles, notamment la dystrophie musculaire de Duchenne (Duchenne), les dystrophies musculaires des ceintures (LGMD) et d'autres troubles neuromusculaires et du système nerveux central (SNC). Elle commercialise trois produits, à savoir EXONDYS 51 (eteplirsen) Injection, VYONDYS 53 (golodirsen) Injection et AMONDYS 45 (casimersen) Injection. Ces produits commerciaux sont indiqués pour le traitement de la maladie de Duchenne chez les patients présentant une mutation confirmée du gène de la dystrophine qui se prête au saut de l'exon 51, de l'exon 53 et de l'exon 45. Son pipeline comprend plus de 40 programmes à différents stades de découverte, de développement préclinique et clinique.
| Industry: | Bio Therapeutic Drugs |
215 1st St Ste 415
CAMBRIDGE
MASSACHUSETTS 02142-1213
US
Compte de résultat
- Annual
- Quarterly
Les gens regardent aussi
Êtes-vous toujours à la recherche d'un broker de confiance?
Rejoignez les plus de 535 000 traders du monde entier qui ont choisi de trader avec Capital.com